GlassScriptPhysician profile
John P Kelley
NPI 1316266133
$24,354.92
in general payments reported to CMS, 2019-2025
40 companies · $7,512 in 2025
The $7,512 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,320 · 2020: $1,714 · 2021: $2,143 · 2022: $2,603 · 2023: $2,842 · 2024: $3,222 · 2025: $7,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,986 · Consulting Fee: $3,433 · Education: $108 · Travel and Lodging: $48.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,986.30 |
| Consulting Fee | $3,432.50 |
| Education | $107.98 |
| Travel and Lodging | $48.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,486.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,498.26 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Galderma Laboratories, L.P. | $2,482.61 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $2,345.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,181.74 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Ars Pharmaceuticals Operations, INC. | $1,736.46 | 2025 | Neffy |
| Csl Behring | $986.22 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $933.32 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $849.34 | 2019-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $688.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $682.59 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Biocryst US Sales Co., LLC | $603.74 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $602.56 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $414.16 | 2021-2023 | Airduo Digihaler |
| Amgen INC. | $396.17 | 2022-2025 | Tezspire, Otezla, Otezla |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $334.22 | 2019-2024 | Auvi-Q |
| Incyte Corporation | $302.80 | 2021-2025 | Opzelura |
| Pharming Healthcare, INC. | $264.70 | 2019-2025 | Ruconest |
| Blueprint Medicines Corporation | $224.36 | 2024-2025 | Ayvakit |
| Octapharma USA, INC. | $186.53 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $147.25 | 2024-2025 | Zoryve |
| Abbvie INC. | $133.92 | 2023-2024 | |
| Alk-Abello, INC | $115.73 | 2020-2023 | Odactra, Grastek |
| Shire North American Group INC | $104.77 | 2019 | |
| Genentech USA, INC. | $86.58 | 2019-2025 | Xolair |
| Hospira, INC. | $66.84 | 2024-2025 | |
| Aytu Biopharma, INC. | $65.32 | 2020-2025 | Karbinal |
| Organon LLC | $65.14 | 2025 | Nexplanon |
| Aimmune Therapeutics, INC. | $64.34 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $45.07 | 2022-2024 | Ryaltris |
| Horizon Therapeutics Plc | $36.56 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.23 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $35.90 | 2024-2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $35.51 | 2020 | |
| Gc Biopharma USA, INC. | $23.40 | 2025 | Alyglo |
| Leo Pharma INC. | $20.66 | 2022 | |
| Mylan Pharmaceuticals INC. | $19.92 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.26 | 2025 | Alvesco |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Phadia US INC. | $15.91 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.